Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of vorinostat versus placebo in previously treated malignant pleural mesothelioma
2005-000949-11Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- May 2005
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pleural mesothelioma comparing Vorinostat plus best supportive care with Placebo plus best supportive care (2 arms). Primary endpoint: Overall survival. Started May 2005; status: terminated.
02
Drugs
vorinostat
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on 2005-000949-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000949-11.